

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Scoping**

**STA Alectinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer**

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

No potential equality issues were identified.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

Not applicable

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No

**Approved by Associate Director (name):** Helen Knight

**Date:** 05/02/2018

Technology Appraisals: Scoping

Equality impact assessment for the Single Technology Appraisal of alectinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer

Issue date: February 2018